--- title: "Ocugen Raises $130 Million Through Convertible Notes Offering" type: "News" locale: "en" url: "https://longbridge.com/en/news/286478287.md" description: "Ocugen has raised $130 million through a private offering of 6.75% Convertible Senior Notes due 2034. The offering included $115 million initially and an additional $15 million from an over-allotment option. The net proceeds of approximately $112.6 million will be used to repay a loan and support corporate purposes, extending the company's cash runway into 2028. The notes may be converted into cash or stock, potentially diluting existing shareholders. Analysts rate OCGN stock as a Buy with a $10.00 price target, though concerns about financial performance and execution risks remain." datetime: "2026-05-14T22:53:11.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286478287.md) - [en](https://longbridge.com/en/news/286478287.md) - [zh-HK](https://longbridge.com/zh-HK/news/286478287.md) --- # Ocugen Raises $130 Million Through Convertible Notes Offering ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Ocugen ( (OCGN) ) has shared an update. On May 7, 2026, Ocugen closed a private offering of $115 million in 6.75% Convertible Senior Notes due 2034 and, on May 14, 2026, issued an additional $15 million after the full exercise of the over-allotment option, bringing the total to $130 million. The notes, sold to qualified institutional buyers at 90% of principal, generated approximately $112.6 million in net proceeds, of which about $32.7 million was used to fully repay Ocugen’s Avenue Capital loan, with the remaining funds earmarked for general corporate purposes and extending the company’s cash runway into 2028 to support three late-stage programs and planned regulatory filings. The notes may be settled in cash, stock or a combination upon conversion, although conversions will be settled solely in cash until a reserved share condition is met, and up to 8,108,108 shares could ultimately be issued, highlighting potential dilution for existing shareholders. By refinancing debt and bolstering liquidity through this Rule 144A convertible issuance, Ocugen strengthens its balance sheet and gains financial flexibility to advance its late-stage ophthalmic pipeline, a development closely watched by institutional investors and stakeholders in the biotech and gene therapy sectors. The most recent analyst rating on (OCGN) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Ocugen stock, see the OCGN Stock Forecast page. **Spark’s Take on OCGN Stock** According to Spark, TipRanks’ AI Analyst, OCGN is a Neutral. Overall score is constrained primarily by weak financial performance (persistent losses, ongoing cash burn, and a stressed balance sheet) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a comparatively strong earnings-call read-through driven by concrete regulatory timelines and positive clinical progress, though financing and execution risks remain key. To see Spark’s full report on OCGN stock, click here. **More about Ocugen** Ocugen, Inc., based in Malvern, Pa., is a biotechnology company focused on gene therapies for blindness diseases. Its modifier gene therapy platform targets inherited retinal disorders and other blindness conditions such as retinitis pigmentosa, Stargardt disease and geographic atrophy, aiming to address large patient populations through a gene-agnostic approach. **Average Trading Volume:** 9,025,329 **Technical Sentiment Signal:** Sell **Current Market Cap:** $497.6M For a thorough assessment of OCGN stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [OCGN.US](https://longbridge.com/en/quote/OCGN.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md) - [Ocugen Advances Late-Stage Gene Therapies, Bolsters Cash Runway](https://longbridge.com/en/news/285244765.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [BUZZ-Ocugen plunges after $115 million convertible bonds offering, bigger loss](https://longbridge.com/en/news/285252501.md) - [Candel Therapeutics Reports Positive Phase 3 Prostate Cancer Trial Data](https://longbridge.com/en/news/286652611.md)